Jeanne Hendrickson, MD
-
RoleBlood Banking and Transfusion Medicine
-
Research Program
-
Practicing Since2008
Background
Jeanne E. Hendrickson, MD, is professor in the Department of Pathology and Laboratory Medicine at Emory University School of Medicine. A pediatric hematologist and transfusion medicine specialist, Dr. Hendrickson's clinical interests include factors influencing alloimmunization, particularly red blood cell alloimmunization, as well as strategies to minimize the formation and dangers of such antibodies.
Dr. Hendrickson serves as medical director of the Hemapheresis Service at Emory University Hospital, and as associate director of the Emory Center for Transfusion and Cellular Therapies.
Titles & Roles
-
Professor, Department of Pathology and Laboratory MedicineEmory University School of Medicine
-
Medical Director, Hemapheresis ServiceEmory University Hospital
-
Associate DirectorEmory Center for Transfusion and Cellular Therapies
Education & Training
Education
- Fellowship, Blood Banking/Transfusion Med., 2008Emory University School of Medicine
- Fellowship, Hematology & Oncology, 2007Emory University School of Medicine
- Fellowship, Pediatric Hematology/Oncology, 2003Emory University School of Medicine
- Residency, Pediatrics, 2002Emory University School of Medicine
- Internship, Pediatrics, 2000Emory University School of Medicine
- Medical Education, MD, 1999Emory University School of Medicine
Board Certifications
- Pediatric Hematology-OncologyAmerican Board of Pediatrics, 2009Blood Banking/Transfusion MedicineAmerican Board of Pathology, 2008PediatricsAmerican Board of Pediatrics, 2002
Research
Dr. Hendrickson's translational research interests include investigating the induction and consequences of red blood cell alloantibodies in transfusion and pregnancy situations, in murine models and in the clinical setting.
Publications
Dr. Hendrickson has authored numerous publications in peer-reviewed journals. She serves on the editorial boards of Transfusion and Blood.
Title/Journal Authors Publication Date Anti-Fy3 in one hospital system: More common than expected.
Transfusion
R Achram, L Arteaga-Cortes, JE Hendrickson 05/20/2025 How I treat challenging transfusion cases in sickle cell disease.
Blood
ST Chou, JE Hendrickson 05/15/2025 Science advances
TC Binns, DA Eaton, DV Akiki, E Deschenes, AS Piotrowski-Daspit, LG Bracaglia, JE Hendrickson, WM Saltzman 05/02/2025 Transfusion
H Yu, MS Karafin, CA Tormey, R Goel, BR Spencer, JE Hendrickson, RG Hauser 03/01/2025 Therapeutic plasma exchange for hyperviscosity syndrome in IgA multiple myeloma.
Laboratory medicine
N Yurtsever, TC Binns, JE Hendrickson, CA Tormey, ES Lee 01/06/2025 Development and evaluation of trigger tools to identify pediatric blood management errors.
Blood transfusion = Trasfusione del sangue
S Kandaswamy, CD Josephson, MR Rollins, J Jones, P Zerra, R Goel, J Andrews, JE Hendrickson, L Lieberman, EW Orenstein 11/01/2024 Journal of clinical apheresis
A Javanbakht, S Stringer, H Anderson, E Hamilton, A Philip, EK Waller, AA Langston, N Joseph, JD Roback, T Schneider, HC Sullivan, JE Hendrickson 06/01/2024 American journal of hematology
S Ito, A Pandya, RG Hauser, L Krishnamurti, E Stites, C Tormey, HM Krumholz, JE Hendrickson, G Goshua 04/01/2024 Red blood cell alloimmunization in patients on extracorporeal membrane oxygenation.
Transfusion
A Javanbakht, TM Schneider, JE Hendrickson 04/01/2024 Antibody-mediated antigen loss switches augmented immunity to antibody-mediated immunosuppression.
Blood
RP Jajosky, KR Patel, JWL Allen, PE Zerra, S Chonat, D Ayona, CL Maier, D Morais, SC Wu, CJ Luckey, SC Eisenbarth, JD Roback, RM Fasano, CD Josephson, JP Manis, L Chai, JE Hendrickson, KE Hudson, CM Arthur, SR Stowell 09/21/2023 Enhanced IgG immune response to COVID-19 vaccination in patients with sickle cell disease.
British journal of haematology
H Nakahara, N Cheedarla, HP Verkerke, S Cheedarla, SC Wu, JE Hendrickson, A Chang, ML McLemore, F El Rassi, JD Roback, AS Neish, RM Fasano, SR Stowell 09/01/2023 Introduction to a How I Treat series on consultative hematology for inpatients.
Blood
JE Hendrickson, TL Ortel 08/31/2023 Transfusion
RA DeSimone, C Plimier, R Goel, JE Hendrickson, CD Josephson, RM Patel, M Sola-Visner, NH Roubinian 08/01/2023 Transfusion therapy for sickle cell disease: what's new?
Blood advances
ST Chou, JE Hendrickson, RM Fasano 06/13/2023 British journal of haematology
JW Jacobs, LD Stephens, ES Allen, TC Binns, GS Booth, JE Hendrickson, MS Karafin, CA Tormey, JS Woo, BD Adkins 06/01/2023 Transfusion
DW Bougie, SE Reese, RJ Birch, DB Bookwalter, PK Mitchell, D Roh, LB Kreuziger, RG Cable, R Goel, J Gottschall, RG Hauser, JE Hendrickson, EA Hod, CD Josephson, S Kahn, SH Kleinman, AE Mast, PM Ness, NH Roubinian, S Sloan 05/01/2023 Class switching is differentially regulated in RBC alloimmunization and vaccination.
Transfusion
A Prakash, J Medved, A Arneja, C Niebuhr, AN Li, S Tarrah, AR Boscia, ED Burnett, A Singh, JE Salazar, W Xu, M Santhanakrishnan, JE Hendrickson, CJ Luckey 04/01/2023 Transfusion
CL Maier, RP Jajosky, SR Patel, HP Verkerke, MD Fuller, JW Allen, PE Zerra, RM Fasano, S Chonat, CD Josephson, DR Gibb, SC Eisenbarth, CJ Luckey, KE Hudson, JE Hendrickson, CM Arthur, SR Stowell 03/01/2023 Class switching is differentially regulated in RBC alloimmunization and vaccination.
bioRxiv : the preprint server for biology
A Prakash, J Medved, A Arneja, C Niebuhr, AN Li, S Tarrah, AR Boscia, ED Burnett, A Singh, JE Salazar, W Xu, M Santhanakrishnan, JE Hendrickson, CJ Luckey 01/12/2023 Transfusion
CA Kerantzas, J Merwede, EL Snyder, JE Hendrickson, CA Tormey, BI Kazmierczak, DR Peaper 12/01/2022 FcγRIV is required for IgG2c mediated enhancement of RBC alloimmunization.
Frontiers in immunology
A Qiu, A Miller, FD Zotti, M Santhanakrishnan, JE Hendrickson, M Tredicine, SR Stowell, CJ Luckey, JC Zimring, KE Hudson 01/01/2022 Ratings & Reviews
Patients who are treated in outpatient and inpatient environments are eligible to receive a survey related to their individual care. Displayed ratings and reviews are displayed for Providers who have received at least 30 returned surveys over a 12-month period and are related to all Care Provider related survey questions. To help our patients better understand our Transparency program (ratings and review), the motivations behind it, how ratings are calculated, why ratings and reviews are not published for every EHC Provider, and how this information can be helpful for our patients, please click here.